(Q44200074)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author

Martin J van den Bent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Andrea Falini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Carmen Balaña

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Olivier Chinot

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

4

Jörg C Tonn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

8

Didier Frappaz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Kirsten Hopkins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Roger Stupp

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Elizabeth Cohen-Jonathan-Moyal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Roger Henriksson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Zvi Ram

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Riccardo Soffietti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Michael Weller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Guido Reifenberger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Wolfgang Wick

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

1 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

e395-403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

Molecular neuro-oncology in clinical practice: a new horizon

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Debulking or biopsy of malignant glioma in elderly people - a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Radiotherapy for glioblastoma in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Temozolomide for high grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Gliomatosis cerebri: molecular pathology and clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Initial chemotherapy in gliomatosis cerebri.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

1 reference

7 January 2021

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Thromboembolic disease in patients with high-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Antiepileptic drugs for preventing seizures in people with brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Antiepileptic drugs for treating seizures in adults with brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Epilepsy and brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Epilepsy meets cancer: when, why, and what to do about it?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Pharmacological treatment of depression in patients with a primary brain tumour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004*

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970011-7

7 January 2021

10.1016/S1470-2045(14)70011-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079102%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference